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INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive disease affect-
ing the respiratory, digestive, endocrine, and reproductive
systems. Although it primarily affects the lungs, disturbances
in the gastrointestinal system is also critical for the manage-
ment of the disease. Management of pancreatic insufficiency
is needed to extend life expectancy and to maintain a good
quality of life (1, 2). The incidence of CF in Caucasian pop-
ulations is about one in 2,500 newborns (3). However, the
disease is very rare in Asian populations. The reported inci-
dence is one in 90,000 Asian infants in Hawaii (4) and one
in 350,000 live births in Japan (5).
To date, only five patients with CF have been reported in
Korea and they all presented with respiratory symptoms rather
than pancreatic insufficiency (6-9). We report a Korean infant
with CF who had steatorrhea and failure to thrive. CF was
confirmed by a sweat chloride test and genetic analysis and
the infant was treated successfully with fat-soluble vitamin
supplementation and pancreatic enzyme replacement therapy.
CASE REPORT
A 9-month-old female infant was admitted to our hospital
because of greasy stools and failure to thrive. She had been well
until two months of age, when a productive cough and fever
developed. She was hospitalized twice with recurrent pneu-
monia, which was treated with antibiotics. At three months
of age, failure to thrive was noted and methicillin-resistant
Staphylococcus aureus (MRSA) was isolated from sputum cul-
tures obtained by ventilating bronchoscopy. At seven months
of age, her parents were aware of her greasy and foul-smelling
loose stools that were often pale; the infant also showed poor
appetite. The patient had been born to a nonconsanguineous
healthy couple by normal spontaneous vaginal delivery at 40
weeks of gestation. The patient’s birth weight was 2.60 kg
and there was no history of delayed passage of meconium.
She had a 6-yr-old brother and the family history was unre-
markable.
On admission, the infant appeared to be malnourished but
was not in acute distress. The body weight was 4.5 kg (<3rd
percentile for age), height 54.7 cm (<3rd percentile), and head
circumference 33 cm (<3 percentile). The patient’s vital signs
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Novel CFTR Mutations in a Korean Infant with Cystic Fibrosis and
Pancreatic Insufficiency
Cystic fibrosis (CF) is an autosomal recessive disease that is very rare in Asians:
only a few cases have been reported in Korea. We treated a female infant with CF
who had steatorrhea and failure to thrive. Her sweat chloride concentration was
102.0 mM/L. Genetic analysis identified two novel mutations including a splice site
mutation (c.1766+2T>C) and a frameshift mutation (c.3908dupA; Asn1303LysfsX6).
Pancreatic enzyme replacement and fat-soluble vitamin supplementation enabled
the patient to get a catch-up growth. This is the first report of a Korean patient with
CF demonstrating pancreatic insufficiency. CF should therefore be considered in
the differential diagnosis of infants with steatorrhea and failure to thrive.
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Accepted : 18 August 2008included a temperature of 36.9℃, heart rate of 130 beats per
minute and respiratory rate of 40 per minute. Her chest was
not retracted and her breathing sounds were clear. The ab-
domen was not distended and the bowel sounds were nor-
mal. There was no organomegaly. No digital clubbing was
found and a neurologic examination was negative.
A complete blood count and serum electrolytes were all
within the normal limits. The serum albumin level was 2.6
g/dL and cholesterol was 100 mg/dL. AST and ALT levels
were 36 U/L and 14 U/L, respectively. Plasma carotene level
was 22.5 μ g/dL (reference range 50-250 μ g/dL). Immuno-
logic studies of the patient were unremarkable, including
normal proportions of polymorphonuclear cells, B cells, CD4
and CD8 T cells, and normal immunoglobulin levels. Stool
fat was demonstrated microscopically. To confirm the pres-
ence of steatorrhea and estimate the quantity of stool fat, an
acidified steatocrit test was performed: this gave a value of
33.3% (reference range; 0-6.5%). Stool alpha-1 antitrypsin
clearance was 0.49 mL over 24 hr, which was within the nor-
mal limits. Chest radiographs and computed tomography
(CT) scans revealed segmental atelectasis and patchy infiltra-
tion. An abdomen CT scan showed normal pancreas and hep-
atobiliary systems.
CF was suspected on the basis of isolation of MRSA in the
respiratory tract, recurrent respiratory infection, and fat mal-
absorption. A quantitative pilocarpine iontophoresis sweat
test was performed, showing the average sweat chloride con-
centration on both thighs to be 102.0 mM/L (reference limit
<40 mM/L). After obtaining informed consent from the par-
ents, genomic DNA was extracted from peripheral blood
leukocytes. Direct sequence analysis of the CF transmem-
brane conductance regulator (CFTR) gene was performed as
described (9). This identified compound heterozygous muta-
tions composed of a novel splicing mutation in intron 12
(c.1766+2T>C) and a 1-bp duplication in exon 21 resulting
in a frameshift mutation (c.3908dupA; Asn1303LysfsX6)
(Fig. 1). The parents declined further genetic analysis and
sweat testing of the family.
Pancreatic enzymes (lipase 25,000 IU), fat-soluble vitamins,
and long-chain polyunsaturated fatty acids were given to treat
the infant’s pancreatic insufficiency. She was fed with breast
milk and standard infant formula. With pancreatic enzyme
replacement, the steatorrhea improved and the infant gained
weight slowly. She was thriving and passing formed stools by
one year after hospital discharge. Her weight was at the 3rd
percentile for age and her height was at the 10th percentile.
DISCUSSION
We describe a Korean infant with CF who had steatorrhea
and failure to thrive. Initially the patient presented with recur-
rent pulmonary infections. Failure to thrive had been regard-
ed as the consequence of chronic pulmonary infections. Chest
CT revealed chronic lung disease and MRSA was cultured
from her sputum. The low plasma carotene level indicated
malabsorption of fat-soluble vitamin A. The increase in acid
steatocrit was indirect evidence of pancreatic insufficiency.
This test can be performed accurately on random spot stools
and can be used to detect the presence of steatorrhea and to
estimate fecal fat quantitatively (10). CFTR sequencing demon-
strated compound heterozygous mutations and the sweat test
was positive, so CF was diagnosed in this patient. Pancreatic
enzyme replacement and fat-soluble vitamin supplementa-
tion led to the improvement of the patient’s steatorrhea and
catch-up growth by one year after discharge from hospital.
Patients are described as having pancreatic insufficiency
when they have measurable steatorrhea, but this does not occur
until only about 1-2% of pancreatic enzymatic secretory capac-
ity remains (11). Pancreatic insufficiency results in the loss
of amylase, lipase, and protease activities, as well as bicarbon-
ate secretion. Lipases are the primary enzymes used to hyd-
rolyze fat which is important in infants and young children
as the primary source of energy. Pancreatic insufficiency is
present in 89% of individuals with CF (12). The remaining
10% of patients have sufficient preservation of pancreatic
function to prevent steatorrhea. Pancreatic function should
be tested for the initial diagnosis of CF and monitored sub-
sequently to delineate any changeover from pancreatic suffi-
ciency to insufficiency (13). Wasting is a significant predic-
tor of survival in patients with CF independent of lung func-
tion. Enzyme therapy improves nutrient absorption and, with
appropriate dietary therapy, normal nutritional status can be
expected in most patients with CF (1).
CF is an autosomal recessive disease caused by mutations
of the gene located on chromosome 7. The gene product is
CFTR, which regulates the transport of electrolytes across epi-
thelial cell membranes (14). More than 1,500 different muta-
tions have been identified so far (http://www.genet.sickkids.
on.ca/cftr/). CFTR mutation patterns in Asian populations
are different from those observed among Caucasians (15, 16).
The F508del genotype, which accounts for 66% of CF cases
worldwide, is very rare in the Korean population (16), and
four mutations reported in Korean patients with CF are not
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Fig. 1. Direct sequencing of the CFTR gene. A novel splice site
mutation (c.1766+2T>C, open arrow) and a novel 1-bp duplica-
tion (c.3908dupA; Asn1303LysfsX6, filled arrow) were identified.commonly seen in Caucasians (8, 9). We found two novel
mutations in this patient, which have not been reported in
Caucasians.
The genotype of CFTR is associated with pancreatic insuf-
ficiency. Previous genotype and phenotype analyses showed
that nonsense, frameshift, and splice junction mutations are
associated with the pancreatic insufficiency phenotype (17).
Mutations leading to CF have grouped into five classes accord-
ing to the mechanism by which the mutation affects normal
CFTR protein function. Class I mutations fail to produce
CFTR proteins because of the presence of nonsense, frameshift,
or splice mutations (18). Our patient harbored a heterozy-
gous splicing mutation and a heterozygous frameshift muta-
tion, which might result in defective production and severe
phenotype. She showed pancreatic insufficiency and required
pancreatic enzyme replacement therapy. Previous Korean
patients with CF, including children and adults, did not show
pancreatic insufficiency (6, 8, 9).
In summary, we treated an infant with CF and pancreatic
insufficiency. CF was diagnosed by a sweat chloride test and
CFTR genetic analysis. Pancreatic enzyme replacement pro-
duced adequate weight gain and resumption of growth in
the patient. CF should be considered in patients with steat-
orrhea and failure to thrive. 
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